Antimicrobial prophylaxis in febrile neutropenia
- PMID: 15250025
- DOI: 10.1086/383058
Antimicrobial prophylaxis in febrile neutropenia
Abstract
Antibiotics generally considered for antibacterial prophylaxis for immunosuppressed patients are trimethoprim-sulfamethoxazole and the quinolones. Trimethoprim-sulfamethoxazole can significantly reduce infections and is highly effective in preventing pneumonia due to Pneumocystis carinii. However, it can cause sulfonamide-related reactions, myelosuppression, oral candidiasis, and development of bacterial resistance, and it lacks activity against Pseudomonas aeruginosa. Quinolones can reduce the occurrence of fever and infections in patients with neutropenia but do not provide adequate coverage against gram-positive bacteria, and inappropriate use can induce resistance among gram-negative organisms. Routine antibacterial prophylaxis is not recommended for patients likely to develop neutropenia. Antifungal prophylaxis is appropriate in settings in which fungal infections are frequent. Fluconazole is recommended for patients who are to undergo hematopoietic stem cell transplantation; it can be considered for elderly patients with acute leukemia who are to receive intensive chemotherapy. Itraconazole can also be used. Prophylaxis with antiviral agents is generally not indicated; however, it should be given to hematopoietic stem cell transplant recipients.
Similar articles
-
Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia.Dan Med Bull. 2001 Nov;48(4):275-7. Dan Med Bull. 2001. PMID: 11767129
-
Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary.Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S49-52. doi: 10.1086/383054. Clin Infect Dis. 2004. PMID: 15250021 No abstract available.
-
[Trimethoprim-sulfamethoxazole as antibacterial prophylaxis during induction therapy of children with acute lymphatic leukemia].Ugeskr Laeger. 2002 Jan 21;164(4):488-92. Ugeskr Laeger. 2002. PMID: 11838420 Danish.
-
Empirical antifungal therapy in treating febrile neutropenic patients.Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S38-43. doi: 10.1086/383052. Clin Infect Dis. 2004. PMID: 15250019 Review.
-
Management of the febrile neutropenic patient: a consensus conference.Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S1-6. doi: 10.1086/383041. Clin Infect Dis. 2004. PMID: 15250013 Review. No abstract available.
Cited by
-
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.Eur J Cancer Care (Engl). 2009 May;18(3):280-6. doi: 10.1111/j.1365-2354.2008.00959.x. Epub 2008 Dec 8. Eur J Cancer Care (Engl). 2009. PMID: 19076208 Free PMC article.
-
Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Support Care Cancer. 2015 Feb;23(2):547-59. doi: 10.1007/s00520-014-2459-x. Epub 2014 Oct 7. Support Care Cancer. 2015. PMID: 25284722 Review.
-
Canadian clinical practice guidelines for invasive candidiasis in adults.Can J Infect Dis Med Microbiol. 2010 Winter;21(4):e122-50. doi: 10.1155/2010/357076. Can J Infect Dis Med Microbiol. 2010. PMID: 22132006 Free PMC article.
-
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.Korean J Intern Med. 2011 Jun;26(2):220-52. doi: 10.3904/kjim.2011.26.2.220. Epub 2011 Jun 1. Korean J Intern Med. 2011. PMID: 21716917 Free PMC article. Review.
-
Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.Support Care Cancer. 2017 Nov;25(11):3515-3521. doi: 10.1007/s00520-017-3775-8. Epub 2017 Jun 6. Support Care Cancer. 2017. PMID: 28584934
MeSH terms
Substances
LinkOut - more resources
Full Text Sources